关于欧普康视科技股份有限公司 2025 年第一次临时股东大会法律意见书 天律意 2025 第 01900 号 天禾律师 股东大会法律意见书 致：欧普康视科技股份有限公司 安徽天禾律师事务所 本法律意见书是天禾律师根据对本次股东大会事实的了解及对我国现行法 律、法规和规范性文件的理解而出具的。 天禾律师同意将本法律意见书作为本次股东大会的法定必备文件予以公告， 并依法对所出具的法律意见书承担责任。 天禾律师根据《证券法》相关规定的要求，按照律师行业公认的业务标准、 道德规范和勤勉尽责精神，对本次股东大会的召集、召开、与会人员资格、表决 程序及其他相关法律问题发表如下意见： 一、关于本次股东大会的召集、召开程序及召集人资格 （一）经验证，根据公司第四届董事会第十六次会议决议，公司于 2025 年 7 月 5 日在巨潮资讯网（http://www.cninfo.com.cn）刊登了《关于召开 2025 年 第一次临时股东大会通知的公告》。 （二）本次股东大会现场会议于 2025 年 7 月 22 日 14:45 在公司会议室召 开，本次股东大会由公司董事会召集，公司董事长陶悦群先生主持。 （三）本次股东大会网络投票 ...

Core Insights - The vision correction industry in China is experiencing rapid growth driven by policy support, market demand, and technological innovation [1][5][22] - The market size is projected to reach 215 billion yuan in 2024, with a year-on-year growth of 11.6% [1][14] - The industry has established a comprehensive treatment system combining surgical and optical correction methods [1][10] Policy Support - The Chinese government has implemented a series of policies to enhance eye health, including the "Comprehensive Prevention and Control of Myopia in Children and Adolescents Implementation Plan" [5][7] - Policies aim to create a management system covering prevention, treatment, and rehabilitation, promoting standardized and high-quality development in the industry [5][22] Market Demand - The number of myopic individuals in China has surpassed 600 million, with a significant increase in myopia rates across all age groups [8][12] - The myopia rate among high school students exceeds 80%, and projections suggest that the rate for the 16-24 age group may reach 94% [8][12] - This growing patient base provides a continuous driving force for the industry's development [1][8] Industry Structure - The vision correction industry has formed a complete industrial chain, with upstream focusing on optical materials and high-end equipment, while midstream includes the production of glasses and surgical devices [10][20] - The downstream market is served by medical institutions, optical centers, and e-commerce platforms, with private eye hospitals contributing over 60% of refractive surgeries [10][12] Competitive Landscape - The industry features a multi-layered competitive structure, with foreign brands dominating high-end markets while domestic brands accelerate their presence [20][21] - Key players include Aier Eye Hospital, Aibo Medical, and Opcon Vision, each with distinct market positions and strategies [21][20] Future Trends - The industry is expected to continue expanding due to policy-driven demand and technological advancements, with a focus on full-cycle management of eye health [22][24] - Innovations such as AI-assisted surgeries and domestic alternatives to imported products are reshaping the competitive landscape [24][25] - The trend towards service accessibility is being driven by private institutions expanding into lower-tier cities and the growth of online sales channels [25][22]

第四届监事会第十七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏 一、监事会会议召开情况 （一）欧普康视科技股份有限公司（以下简称"公司"）第四届监事会第十 七次会议，于 2025 年 7 月 14 日以专人送达、即时通讯等方式发出会议通知。 （二）会议于 2025 年 7 月 18 日以现场形式召开。 证券代码：300595 证券简称：欧普康视 公告编号：2025-058 欧普康视科技股份有限公司 具体内容详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）披露的 《关于部分募投项目结项并将节余募集资金永久补充流动资金及注销募集资金 专户的公告》。 本议案需提交股东大会审议。 三、备查文件 （三）本次会议应参与表决监事 3 人，实际参与表决监事 3 人。 （四）会议由监事会主席孙永建先生主持。 （五）本次会议召开符合《公司法》和《公司章程》的有关规定。 二、监事会会议审议情况 经投票表决，会议审议通过如下决议： 以 3 票赞成，0 票反对，0 票弃权审议通过《关于部分募投项目结项并将节 余募集资金永久补充流动资金及注销募 ...

关于部分募投项目结项并将节余募集资金永久补充流动资 金及注销募集资金专户的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 欧普康视科技股份有限公司（以下简称"公司"或"欧普康视"）2025 年 7 月 18 日召开第四届董事会第十七次会议和第四届监事会第十七次会议,分别审 议通过了《关于部分募投项目结项并将节余募集资金永久补充流动资金及注销 募集资金专户的议案》。鉴于公司向特定对象发行股票募集资金投资项目"接 触镜和配套产品产业化项目"达到预定可使用状态，同意公司将该项目结项， 并将节余募集资金 13,400.08 万元（包含现金管理净收益和利息净收入，具体 金额以资金转出当日银行结息余额为准，下同）永久补充流动资金，用于公司 日常经营活动，同时注销相关募集资金专项账户并授权管理层及财务部门办理 募集资金专户销户相关事项。募投项目尚需支付的部分合同尾款将由自有资金 支付。本事项尚需提交公司股东大会审议。现将有关事项说明如下： 证券代码：300595 证券简称：欧普康视 公告编号：2025-059 欧普康视科技股份有限公司 一、募集资金的基本情况 经中国证 ...

欧普康视科技股份有限公司 第四届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 （一）欧普康视科技股份有限公司（以下简称"公司"）第四届董事会第十 七次会议，于 2025 年 7 月 14 日以专人送达、即时通讯等方式发出会议通知。 证券代码：300595 证券简称：欧普康视 公告编号：2025-057 独立董事专门会议已审议通过本议案，保荐机构出具了核查意见。具体内容 详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）披露的《关于部分募 投项目结项并将节余募集资金永久补充流动资金及注销募集资金专户的公告》。 1 （二）会议于 2025 年 7 月 18 日以通讯形式召开。 （三）本次会议应参与表决董事 9 人，实际参与表决董事 9 人。 （四）本次会议由董事长陶悦群先生主持，公司全体监事、高级管理人员列 席会议。 （五）本次会议召开符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 经投票表决，会议审议通过如下决议： 以 9 票赞成，0 票反对，0 票弃权审议通过《关 ...

国元证券股份有限公司 关于欧普康视科技股份有限公司部分募投项目结项 并将节余募集资金永久补充流动资金及注销募集资金专户 的核查意见 国元证券股份有限公司（以下简称"国元证券"或"保荐机构"）作为欧普 康视科技股份有限公司（以下简称"欧普康视"或"公司"）向特定对象发行股 票的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业 板股票上市规则》《上市公司募集资金监管规则》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》等有关规定，对欧普康视部分 募投项目结项并将节余募集资金永久补充流动资金及注销募集资金专户事项进 行了审慎核查，核查情况如下： 三、本次结项募投项目募集资金的存储及节余情况 公司本次结项的募集资金投资项目为"接触镜和配套产品产业化项目"。截 至 2025 年 6 月 30 日，上述项目已达到预定可使用状态，满足结项条件。 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意欧普康视科技股份有限公司向特定对 象发行股票注册的批复》（证监许可〔2021〕3405 号）核准，公司于 2022 年 6 月向特定对象发行人民币普通股（A 股）42,594,8 ...

Group 1 - The core point of the article highlights that Opcon Vision is engaging in a high-stakes transformation gamble by acquiring 75% of Shangyue Qicheng for 334 million yuan, despite the target's net asset value being only 52.14 million yuan, resulting in a staggering valuation increase of 753.86% [1][2] - The acquisition is tied to stringent performance guarantees, requiring a compound annual growth rate of over 14% in net profit from 2025 to 2029, and a total net profit of no less than 296 million yuan from 2030 to 2034 [2] - The company's revenue growth has drastically slowed to 4.4% in 2024, with a net profit decline of 14.16%, marking the worst performance since its listing, leading to a market value drop of nearly 80 billion yuan over four years [2] Group 2 - The funding for the acquisition raises concerns as 234 million yuan was redirected from previously abandoned fundraising projects, including a community eye care service project that has only seen 10.01% investment progress [3] - The company claims the acquisition will enhance its strategy of "full vision products + services for all age groups," but the high premium and future performance commitments raise significant risks [4] - The era of relying on a single blockbuster product is over, and the company faces uncertainty in whether this acquisition can revitalize its market position after the decline of its flagship OK lens business [4]

证券代码：300595 证券简称：欧普康视 公告编号：2025-056 欧普康视科技股份有限公司 关于持股5%以上股东部分股份质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 欧普康视科技股份有限公司（以下简称"公司"）于近日收到公司持股 5% 以上股东南京欧陶信息科技有限公司（以下简称"南京欧陶"）通知，获悉其将 持有公司股份 270 万股在中信建投证券股份有限公司办理了质押。现将具体情况 公告如下： 一、股东股份质押的基本情况 | | 是否为控 | | 占其 | 占公 | | 是否 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股股东或 | 本次质押数 | 所持 | 司总 | 是否 | 为补 | 质押 | 质押 | | 质押 | | 名称 | 第一大股 | 量（股） | 股份 | 股本 | 为限 | 充质 | 起始日 | 到期日 | 质权人 | 用途 | | | 东及其一 | | 比例 | 比例 | 售股 | 押 | | | ...

Group 1 - The article highlights the rising costs and pressures faced by parents regarding their children's health, particularly in managing myopia, dental issues, and height concerns [2][57] - A significant market has emerged around myopia treatment, with the overall myopia rate among children and adolescents in China reaching 52.7%, indicating that one in two children is affected [27][28] - Companies in the myopia treatment sector, such as Opcon Vision and Aier Eye Hospital, are experiencing substantial revenue growth, with Opcon Vision's revenue reaching 1.814 billion and Aier Eye Hospital's revenue at 20.983 billion [30][31] Group 2 - The orthodontics market is also booming, with companies like Times Angel and Invisalign dominating the space, capturing significant market shares and generating substantial revenues [43][44] - The article discusses the high costs associated with dental treatments, with some families spending up to 60,000 on orthodontic solutions, reflecting a growing trend in dental care for children [34][36] - The prevalence of dental issues among children is alarming, with a reported 67.82% incidence of malocclusion, leading to increased demand for orthodontic services [41] Group 3 - Height management is emerging as a new area of concern for parents, with the market for growth hormone treatments and related products projected to reach 8-12 billion, growing at a compound annual growth rate of over 25% [56][57] - Companies like Jinsai Pharmaceutical are leading the growth in the height management sector, with a reported revenue of 10.67 billion, indicating a strong market presence [56] - The societal pressures regarding height are reflected in the increasing willingness of parents to invest heavily in treatments, with some spending tens of thousands on growth hormone therapies [48][49]

Core Viewpoint - The company Oupankangshi has announced that its subsidiary Jiangsu Duzi Medical Technology Co., Ltd. has had its application for the medical device "soft hydrophilic contact lens" accepted by the National Medical Products Administration of China, marking a significant step towards product registration and market entry [1] Group 1 - The product is classified as a Class III medical device in China, intended for daily wear to correct refractive errors [1] - The application has been assigned the acceptance number CQZ2501262 and is currently in the registration application acceptance stage [1] - The product has undergone clinical research and usage both domestically and internationally, with good sales performance in the global market [1] Group 2 - There are already similar products available in the domestic market, indicating a competitive landscape [1] - The product must pass technical review to obtain the registration certificate before it can be produced and sold [1]